Remanent Activation in the Mini-SHINE Experiments

Conference · Thu Apr 16 00:00:00 EDT 2015

OSTI ID:1402069

Micklich, Bradley J.

Argonne National Laboratory is assisting SHINE Medical Technologies in developing a domestic source of the medical isotope 99Mo through the fission of low-enrichment uranium in a uranyl sulfate solution. In Phase 2 of these experiments, electrons from a linear accelerator create neutrons by interacting in a depleted uranium target, and these neutrons are used to irradiate the solution. The resulting neutron and photon radiation activates the target, the solution vessels, and a shielded cell that surrounds the experimental apparatus. When the experimental campaign is complete, the target must be removed into a shielding cask, and the experimental components must be disassembled. The radiation transport code MCNPX and the transmutation code CINDER were used to calculate the radionuclide inventories of the solution, the target assembly, and the shielded cell, and to determine the dose rates and shielding requirements for selected removal scenarios for the target assembly and the solution vessels.

• Research Organization: Argonne National Lab. (ANL), Argonne, IL (United States)
• Sponsoring Organization: USDOE National Nuclear Security Administration (NNSA) - Office of Defense Nuclear Nonproliferation - Office of Material Management and Minimization (M3); USDOE Office of Science (SC), Basic Energy Sciences (BES)
• DOE Contract Number: AC02-06CH11357
• OSTI ID: 1402069
• Resource Relation: Conference: 2015 Workshop on Accelerator Radiation Induced Activation, 04/15/15 - 04/17/15, Knoxville, TN, US
• Country of Publication: United States
• Language: English